Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
ZacksBiorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?